文献速递肿瘤 PET/CT核素与放射性配体治疗

肾上腺皮质癌中18F-FDG摄取与肿瘤增殖抗原Ki-67表达呈正相关

Positive Correlation Between 18 F-FDG Uptake and Tumor-Proliferating Antigen Ki-67 Expression in Adrenocortical Carcinomas.
PubMed 文献 · Clin Nucl Med · 2023-02-08

该队列研究纳入63例经组织学证实的肾上腺皮质癌患者(55例ACC及8例伴类固醇过度分泌的转移性ACC),所有患者接受18F-FDG PET检查并计算SUVmax及肾上腺与肝脏SUVmax比值。结果显示56/63例(89%)肾上腺与肝脏SUVmax比值>1.45,7例(11%)摄取较低;PET参数与肿瘤大小、ENSAT分期、Weiss评分及Ki-67呈正相关,SUVmax与Ki-67强相关(r=0.47,P=0.0009),但PET参数与无进展生存或总生存无统计学显著关联。

要点

  • 63例肾上腺皮质癌中56例(89%)肾上腺与肝脏SUVmax比值>1.45,为既往定义的预测恶性临界值(灵敏度100%)。
  • 7例(11%)肾上腺与肝脏SUVmax比值<1.45,多数Ki-67表达水平<10%。
  • SUVmax与Ki-67呈强正相关(r=0.47,P=0.0009),提示18F-FDG摄取水平与肿瘤增殖相关。

核心结论

  • 该大型队列研究显示大多数肾上腺皮质癌病例表现出高18F-FDG摄取,但SUVmax与Ki-67表达水平之间的正相关似乎可解释部分ACC呈现低或无18F-FDG摄取的可能性。
  • 这些发现对肾上腺肿块患者的管理具有实际意义。

研究设计与样本

  • 组装了一个63例经组织学证实的肾上腺皮质癌(n=55)或伴类固醇过度分泌的转移性肾上腺皮质癌(n=8)患者队列。
  • 所有患者接受18F-FDG PET检查,计算SUVmax及肾上腺与肝脏SUVmax比值,并将PET参数与临床、病理及结局数据进行比较。

主要发现

  • 63例患者中56例(89%)肾上腺与肝脏SUVmax比值>1.45,该值为既往定义的预测恶性临界值(灵敏度100%)。
  • 7例肾上腺皮质癌(11%)摄取较低(肾上腺与肝脏SUVmax<1.45),其中多数增殖标志物Ki-67表达水平<10%。
  • 18F-FDG PET参数(SUVmax及肾上腺与肝脏SUVmax比值)与肿瘤大小、ENSAT分期、总Weiss评分及Ki-67呈正相关。
  • SUVmax与Ki-67呈强相关(r=0.47,P=0.0009),提示18F-FDG摄取水平与肿瘤增殖之间存在关系。
  • 结局参数(无进展生存或总生存)与18F-FDG PET参数之间未发现统计学显著关联。

关键数值与推荐

  • 肾上腺与肝脏SUVmax比值>1.45为既往定义的预测恶性临界值,灵敏度100%。
  • SUVmax与Ki-67的相关系数r=0.47,P=0.0009。

临床怎么用

  • 原文结论指出这些发现对肾上腺肿块患者的管理具有实际意义,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: Adrenocortical carcinoma (ACC) is an extremely rare endocrine malignancy, which cannot always be diagnosed during conventional radiology and hormonal investigations. 18 F-FDG PET could help predict malignancy, but more data are necessary to support future guidelines. METHODS: A cohort of 63 patients with histologically proven ACC (n = 55) or metastatic ACC with steroid oversecretion (n = 8) was assembled. All patients underwent an 18 F-FDG PET, and the SUV max and the adrenal-to-liver SUV max ratio were calculated. The 18 F-FDG PET parameters were compared with clinical, pathological, and outcome data. RESULTS: Fifty-six of 63 patients (89%) had an ACC with an adrenal-to-liver SUV max ratio >1.45, which was a previously defined cutoff value to predict malignancy with 100% sensitivity. Seven ACCs (11%) had a lower uptake (adrenal-to-liver SUV max <1.45), most of them with a proliferation marker Ki-67 expression level <10%. A positive correlation between 18 F-FDG PET parameters (SUV max and adrenal-to-liver SUV max ratio) and tumor size, ENSAT (European Network for the Study of Adrenal Tumors) staging, total Weiss score, and the Ki-67 was found. The strong correlation between SUV max and Ki-67 ( r = 0.47, P = 0.0009) suggests a relationship between 18 F-FDG uptake levels and tumor proliferation. No statistically significant associations between outcome parameters (progression-free or overall survival) and 18 F-FDG PET parameters were found. CONCLUSIONS: This large cohort study shows that most cases of ACC demonstrate high 18 F-FDG uptake. However, the positive correlation observed between SUV max and Ki-67 expression levels seems to explain the possibility of identifying some ACC with a low or inexistent 18 F-FDG uptake. These findings have practical implications for the management of patients with an adrenal mass.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Libé R, Pais A, Violon F, et al. Positive Correlation Between 18 F-FDG Uptake and Tumor-Proliferating Antigen Ki-67 Expression in Adrenocortical Carcinomas. Clin Nucl Med. 2023. PMID: 36758555. doi:10.1097/RLU.0000000000004593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。